
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The global RSV diagnostics market was valued at USD 1028.55 Million in 2024, driven by growing awareness of the severity and impact of respiratory syncytial virus (RSV) infections across the globe. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034, with the values likely to reach USD 2716.70 Million by 2034.
Base Year
Historical Period
Forecast Period
Rising global RSV prevalence, especially among infants and the elderly, continues to drive demand for fast, reliable diagnostic solutions.
Innovative newborn testing solutions like Thermo Fisher’s RSV Combo Kit are boosting early detection rates and market penetration across pediatric segments.
The expansion of high-throughput multiplex systems, such as Roche's cobas LIAT and Hologic's Fusion Assay, is enhancing diagnostic efficiency globally.
Compound Annual Growth Rate
10.2%
Value in USD Million
2025-2034
RSV Diagnostics Market Outlook
*this image is indicative*
Respiratory syncytial virus (RSV) continues to be a leading cause of acute lower respiratory infections globally, with an estimated 33 million infections, 3.6 million hospitalizations, and 100,000 deaths annually in children under five, as reported by the National Institutes of Health (NIH). In the United States alone, the CDC estimates 58,000-80,000 RSV-related hospitalizations among children and up to 160,000 hospitalizations in adults aged 65+ each year, with 6,000–10,000 resulting deaths in the older population. These alarming figures underscore the urgency of early and reliable diagnostic solutions. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034.
Newborn Testing Innovations to Fuel Market Growth
In March 2025, Thermo Fisher Scientific introduced its TaqPath RSV Combo Kit, cleared for use in neonates and pediatric populations. This multiplex RT-PCR test can simultaneously detect RSV, influenza A and B in under two hours. The advancement allows early intervention among the most vulnerable age groups, addressing pediatric RSV hospitalization rates. Such innovations contribute significantly to market expansion by enabling accurate, early detection and reducing disease progression in high-risk newborn populations.
The market is witnessing trends like rising adoption of point of care testing, enhancements in molecular quality control to boost efficiency, innovations in diagnostics to provide better solutions to the patients.
Advancements in Multiplex and High-Throughput Testing Drive Market Growth
The market is witnessing accelerated expansion due to innovations in high-throughput and multiplex testing platforms. For instance, in June 2024, Roche’s cobas® LIAT system received EUA for a 20-minute test detecting RSV, COVID-19, and influenza from a single nasal swab. Hologic’s Panther Fusion Assay, approved in May 2023, enables scalable RSV detection in centralized labs. These rapid and integrated technologies improve diagnostic efficiency, enhance patient triaging, and reduce time-to-treatment across clinical and public health settings.
Preference for Point-of-Care Advancements to Accelerate RSV Diagnostic Market Growth
In May 2025, SEKISUI Diagnostics launched the OSOM® RSV Test, a CLIA-waived rapid immunochromatographic assay that detects RSV nucleoprotein antigens in just 15 minutes. Designed for broader demographic coverage, it is approved for children aged 6 months to 6 years and adults aged 60 and older. This innovation enhances rapid diagnostic capabilities in professional healthcare settings, particularly for high-risk groups, which supports faster treatment decisions and improves clinical outcomes.
Advancements in Molecular Quality Controls to Fuel RSV Diagnostics Market Demand
In May 2025, Bio-Rad Laboratories received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls. Although these initially focus on pathogens such as HPV, CT/NG, and SARS-CoV-2, the underlying technological and regulatory progress significantly benefits the broader molecular diagnostics market, including RSV. These quality controls simulate patient specimens, enhancing test accuracy and reliability, key factors in RSV diagnostics. As regulatory frameworks evolve, diagnostic companies are incentivized to enhance test performance across all infectious diseases, RSV included.
Adoption of Human Challenge Models to Impact the RSV Diagnostics Market Size Positively
In September 2024, UK-based hVIVO advanced its human disease modeling platform to accelerate respiratory and infectious disease drug discovery, including for RSV. By conducting early clinical development and human challenge trials, hVIVO provides pharma clients with reliable RSV testing environments. The company’s work, including laboratory services under hLAB and field trial recruitment via FluCamp, reinforces RSV diagnostic research and positions human challenge models as vital tools in pipeline validation.
Hospitals to Lead the Segmentation by End User
The hospitals segment is expected to hold the largest market share, accounting for over 41% during the historical period. This dominance is driven by hospitals’ critical role in managing high-risk RSV cases, especially among infants and the elderly. Their reliance on advanced diagnostic tools, including molecular and immunoassay-based tests, ensures timely interventions and supports accurate clinical decisions. Additionally, high patient inflow and the need for rapid testing contribute to hospitals’ sustained leadership in RSV diagnostics adoption.
North America is expected to dominate the market due to the extensive adoption of multiplex molecular platforms and strong CDC-led surveillance programs supporting early RSV detection. It accounted for the largest revenue share in the market, capturing approximately 41 % of the total market value. High testing rates during peak seasons, particularly among pediatric and elderly populations, contribute to this lead. Europe follows, driven by government-supported diagnostic reimbursement schemes and the regional launch of high-throughput RSV detection systems like Roche’s cobas® and Panther Fusion. These factors collectively reinforce diagnostic accessibility and lab integration across both regions.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD is a global medical technology company offering diagnostic systems, medical devices, and laboratory equipment. In the RSV diagnostics market, BD provides rapid antigen tests such as the BD Veritor™ Plus System, which delivers results for RSV and other respiratory pathogens within minutes. These point-of-care solutions support accurate, timely diagnosis in clinical settings and are widely adopted across hospitals, urgent care centers, and physician offices.
Thermo Fisher Scientific, established in 2006 and based in Waltham, Massachusetts, is a global leader in scientific research services and diagnostics. Its portfolio in the RSV diagnostics market includes advanced molecular diagnostic tools such as TaqPath™ multiplex real-time PCR assays and Applied Biosystems platforms. These high-sensitivity solutions enable the simultaneous detection of RSV, influenza, and SARS-CoV-2, supporting accurate differential diagnosis in clinical laboratories worldwide, particularly during peak respiratory seasons.
Founded in 1952 and headquartered in Hercules, California, Bio-Rad Laboratories specializes in life science research and clinical diagnostics. In the RSV diagnostics segment, Bio-Rad offers immunoassays and PCR-based testing tools through its respiratory pathogen panels, which allow simultaneous detection of multiple viruses, including RSV. These diagnostics cater to both research and clinical laboratories, enhancing surveillance and testing efficiency during viral outbreaks. The company is known for its precision instruments and reagent systems in infectious disease diagnostics.
Headquartered in Basel, Switzerland, and established in 1896, F. Hoffmann-La Roche Ltd. is a global pharmaceutical and diagnostics company. Its presence in the RSV diagnostics market is marked by the cobas® LIAT and cobas® 6800/8800 systems, offering rapid molecular testing with high throughput. These systems support multiplex detection of RSV, influenza, and COVID-19, with results available in under 20 minutes for certain assays. Roche’s innovations are widely implemented in hospitals and centralized laboratories across global markets.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include BIOMÉRIEUX, DiaSorin S.p.A., Coris BioConcept, Quest Diagnostics Incorporated, Cepheid (Danaher Corporation), and Johnson & Johnson MedTech.
"RSV Diagnostics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Offerings
Market Breakup by Method
Market Breakup by End User
Market Breakup by Region
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The global RSV diagnostics market attained a value of nearly USD 1028.55 Million in 2024.
The market is projected to grow at a CAGR of 10.20% in the forecast period of 2025-2034.
The market is estimated to witness a healthy growth in the forecast period of 2025-2034 to reach about USD 2716.70 Million by 2034.
The market is being driven by the rising prevalence of RSV disorder, especially amongst children below the age of two and the resultant requirement for an effective diagnostic solution.
Improvements in diagnostics technology and robust investments into the research and development (R&D) activities are expected to aid the market growth in the coming years.
The major regional markets for RSV diagnostics are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
The major products of RSV diagnostics are direct fluorescent antibody (DFA) method, rapid antigen diagnostic test (RADT), molecular diagnostics, chromatographic immunoassay, diagnostic imaging, gel microdroplets, and flow cytometry, among others.
The major end-uses of RSV diagnostics are hospitals, laboratory, clinics, and homecare.
The major players in the industry are Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, bioMérieux SA, and DiaSorin Molecular LLC, among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2024 |
Historical Period | 2018-2024 |
Forecast Period | 2025-2034 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Offerings |
|
Breakup by Method |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.